Published in Nature Genetics · View the paper (DOI)
A Vanderbilt-led study identifies a compound that can reverse the malignant reprogramming of metastatic pancreatic cancer cells. The research found that distant metastases undergo massive epigenetic changes that enable tumor formation, but these changes can be reversed with the inhibition of phosphogluconate dehydrogenase enzyme.
Coverage from 2 institutions
- Metastatic pancreatic cancer 'reprogrammed' for malignancy Vanderbilt University Medical Center · Jan 16, 2017 · first to report
- Potentially reversible changes in gene control 'prime' pancreatic cancer cells to spread Johns Hopkins Medicine · Jan 16, 2017